Oprozomib
Sponsors
Amgen
Conditions
Advanced Hepatocellular CarcinomaAdvanced Non-Central Nervous System (CNS) MalignanciesMultiple MyelomaSolid TumorsWaldenstrom Macroglobulinemia
Phase 1
Phase 1 Study of Oprozomib Administered Orally in Patients With Advanced Refractory or Recurrent Solid Tumors
CompletedNCT01129349
Start: 2010-04-30End: 2013-03-31Updated: 2017-05-02
Open-label Study of the Safety and Activity of Oprozomib in Patients With Hematologic Malignancies
TerminatedNCT01416428
Start: 2011-10-15End: 2019-08-12Updated: 2022-11-08
Phase 1b/2, Multicenter, Open-label Study of Oprozomib and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma
TerminatedNCT01832727
Start: 2013-07-02End: 2019-06-25Updated: 2020-07-13
Oprozomib and Dexamethasone,in Combination With Lenalidomide or Oral Cyclophosphamide to Treat Newly Diagnosed Multiple Myeloma
TerminatedNCT01881789
Start: 2013-10-28End: 2019-09-23Updated: 2022-11-14
A Study of Oprozomib, Pomalidomide, and Dexamethasone in Adults With Primary Refractory or Relapsed and Refractory Multiple Myeloma
TerminatedNCT01999335
Start: 2014-07-30End: 2019-04-25Updated: 2021-04-27
A Study of Oprozomib, Melphalan, and Prednisone in Transplant Ineligible Patients With Newly Diagnosed Multiple Myeloma
CompletedNCT02072863
Start: 2014-01-31End: 2015-09-30Updated: 2017-05-02
Phase 1b/2 Study of Oprozomib in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma
WithdrawnNCT02227914
Start: 2014-12-31End: 2015-03-31Updated: 2017-05-02
A Phase 1 Study of Oprozomib to Assess Food Effect, Drug-Drug Interaction With Midazolam, and Safety and Tolerability in Patients With Advanced Malignancies
TerminatedNCT02244112
Start: 2014-08-31End: 2019-07-10Updated: 2021-02-21